Feb. 19, 2013 /PRNewswire/ -- Endexx Corporation (OTC Markets: EDXC) announces that it has entered into a Letter of Agreement and Memorandum of Understanding to purchase and acquire from Hayes Pharmacy Inc. (a Texas Corporation), the exclusive operating technology, intellectual property, marketing and ownership rights to a proprietary pharmaceutical/pharmacy compliance, controls, privacy, verification and operations platform. The platform is specifically designed to service the medical marijuana industry and long term chronic pharmaceutical patient care arena. Upon completion of due diligence and closing of the transaction, Endexx will report details of the business going forward.
Contact: Todd Davis CEO
Safe Harbor Statement
This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including statements regarding potential sales, the success of the company's business, as well as statements that include the word "believe" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Endexx to differ materially from those implied or expressed by such forward-looking statements. This press release speaks as of the date first set forth above, and Endexx assumes no responsibility to update the information included herein for events occurring after the date hereof. Actual results could differ materially from those anticipated due to factors such as the lack of capital, timely development of products, inability to deliver products when ordered, inability of potential customer to pay for ordered products, and political and economic risks inherent in international trade.
SOURCE Endexx Corporation
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts